SCHEMBL14626401

SCHEMBL14626401

COC(=O)N1CCc2cccc(C)c2C1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 6/20 0.51
NPC1 O15118 5/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
ABHD6 Q9BV23 2/20 0.48
ALDH1A1 P00352 1/20 0.48
CYP3A4 P08684 1/20 0.48
CYP2C9 P11712 1/20 0.48
HPGD P15428 1/20 0.48
CYP2C19 P33261 1/20 0.48
HTT P42858 1/20 0.48
TMEM97 Q5BJF2 1/20 0.46
SIGMAR1 Q99720 1/20 0.46
POLB P06746 1/20 0.45
KIF11 P52732 1/20 0.45
NOTUM Q6P988 2/20 0.45
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
TAS1R3 Q7RTX0 1/20 0.43
TAS1R1 Q7RTX1 1/20 0.43
TAS1R2 Q8TE23 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19608875 0.84 ESR2 (0.56) ABHD6ALDH1A1CYP3A4CYP2C9HPGD
SCHEMBL14591318 0.83 NOTUM (0.65) RAB9ANPC1SMN1; SMN2ALDH1A1CYP3A4
SCHEMBL30726807 0.83 ALDH1A1 (0.51) RAB9ANPC1SMN1; SMN2ABHD6ALDH1A1
SCHEMBL6341159 0.82 HPGD (0.51) RAB9ANPC1SMN1; SMN2ABHD6ALDH1A1
SCHEMBL14591323 0.81 ALDH1A1 (0.50) RAB9ANPC1SMN1; SMN2ABHD6ALDH1A1
SCHEMBL30056523 0.81 NOTUM (0.67) RAB9ANPC1SMN1; SMN2ABHD6ALDH1A1
SCHEMBL464005 0.81 NOTUM (0.67) RAB9ANPC1SMN1; SMN2ABHD6ALDH1A1
SCHEMBL14591400 0.79 TMEM97 (0.55) ABHD6CYP2C19TMEM97SIGMAR1DRD2
SCHEMBL14591488 0.79 DRD2 (0.48) RAB9ANPC1SMN1; SMN2ALDH1A1CYP3A4
SCHEMBL6097273 0.79 NOTUM (0.58) RAB9ANPC1SMN1; SMN2ABHD6ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130149281-A1 ORGANIC COMPOUNDS AND THEIR USES NOVARTIS AG (CH) 2013-06-13 US disclosed
US-7157463-B2 Substituted piperidines/piperazines as melanocortin receptor agonists ELI LILLY AND COMPANY (US) 2007-01-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130149281-A1 ORGANIC COMPOUNDS AND THEIR USES OAT, HAVCR2, CPT1A RAB9A 3121/4885NPC1 27/4885SMN1; SMN2 1149/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.